Game-Changer Alert: FDA Greenlights Viatris and Ocuphire’s Innovative Eye Drops to Swiftly Restore Pupils!

In an exciting development, the FDA has granted approval for the groundbreaking phentolamine ophthalmic solution jointly created by Ocuphire and Viatris. This innovative eye drop, now named Ryzvumi, is set to revolutionize the reversal of pharmacologically-induced mydriasis, or pupil dilation.

Ryzvumi comes as a ray of hope for patients who have undergone chemically-induced eye dilation using adrenergic agonists or parasympatholytic agents. Unlike other medications, Ryzvumi doesn’t carry a boxed warning. However, its label does caution against potential side effects, including uveitis, site discomfort, and conjunctival hyperemia. The dynamic pharmaceutical duo anticipates launching Ryzvumi in the United States during the first half of 2024.

Jeffrey Nau, President of Viatris Eye Care division, highlighted the significance of comprehensive dilated eye exams for early disease detection. In the U.S., approximately 100 million such exams are conducted each year, often necessitating the use of pharmacological agents to induce pupil dilation.

Nau stated, “Our hope is that by addressing patient dilation barriers, we’re empowering eye care professionals to broaden exam availability, leading to enhanced eye health outcomes.”

Pharmacologically-induced pupil dilation can last anywhere from six to 24 hours, impacting patients’ sensitivity to light and ability to focus on nearby objects. This can disrupt their daily routines, from driving and working to reading.

Ryzvumi takes a unique approach, leveraging its non-selective agonist activity against alpha-1 and alpha-2 adrenergic receptors found on the iris dilator muscles. By activating these receptors, Ryzvumi effectively narrows the pupil, alleviating the inconvenience caused by prolonged dilation.

The FDA’s approval was underpinned by data from the comprehensive MIRA clinical trial program, involving over 600 patients across multiple phases. These trials, including Phase IIb and pivotal Phase III studies, along with a pediatric trial, showcased Ryzvumi’s superior performance compared to a placebo in restoring baseline pupil diameter. Additionally, the MIRA program confirmed the eye drops’ favorable safety and tolerability profile.

Originally known as Nyxol and developed by Ocuphire, Ryzvumi’s journey gained momentum with a licensing agreement between Ocuphire and FamyGen Life Sciences in November 2022, spanning the U.S., Europe, Japan, and other territories.

Viatris, on a mission to bolster its eye care division, completed its acquisition of Famy, alongside Oyster Point Pharma, in January 2023. The move was a strategic step toward expanding their portfolio and commercial reach, with projections of adding at least $1 billion in sales by 2028. As they embark on this transformative journey, Ryzvumi takes center stage as a pioneering solution for the world of eye care.”

Leave a Comment